SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Not yet recruiting · NCT07234721 · Registry updated 2026-02-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Early phase 1 | 2026-02-10 | NCT07234721 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hebei Senlang Biotechnology Inc., Ltd. | 14 |
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||